[Lab on a chip] Application of a strain rate gradient microfluidic device to von Willebrand's di
Von Willebrand's disease (VWD) is the most common inherited bleeding disorder caused by either quantitative or qualitative defects of von Willebrand factor (VWF). Current tests for VWD require relatively large blood volumes, have low throughput, are time-consuming, and do not incorporate the physiologically relevant effects of haemodynamic forces. We developed a microfluidic device incorporating micro-contractions that harnesses well-defined haemodynamic strain gradients to initiate platelet aggregation in citrated whole blood. The microchannel architecture has been specifically designed to allow for continuous real-time imaging of platelet aggregation dynamics. Subjects aged ≥18 years with previously diagnosed VWD or who presented for evaluation of a bleeding disorder, where the possible diagnosis included VWD, were tested. Samples were obtained for device characterization as well as for pathology-based testing. Platelet aggregation in the microfluidic device is independent of platelet amplification loops but dependent on low-level platelet activation, GPIb/IX/V and integrin αIIbβ3 engagement. Microfluidic output directly correlates with VWF antigen levels and is able to sensitively detect aggregation defects associated with VWD subtypes. Testing demonstrated a strong correlation with standard clinical laboratory-based tests. Head-to-head comparison with PFA100® demonstrated equivalent, if not improved, sensitivity for screening aggregation defects associated with VWD. This strain rate gradient microfluidic prototype has the potential to be a clinically useful, rapid and high throughput-screening tool for VWD as well as other strain-dependent platelet disorders. In addition, the microfluidic device represents a novel approach to examine the effects of high magnitude/short duration (ms) strain rate gradients on platelet function.
Rose J. Brazilek,a Francisco J. Tovar-Lopez,ab Angus K. T. Wong,a Huyen Tran,ac Amanda S. Davis,c James D. McFadyen,c Zane Kaplan,ac Sanjeev Chunilal,e Shaun P. Jackson,d Harshal Nandurkar,ac Arnan Mitchellb and Warwick S. Nesbitt*ab
aThe Australian Centre for Blood Diseases, Monash University, Alfred Medical Research and Educational Precinct, Melbourne, Australia
bMicroplatforms Research Group, School of Engineering, RMIT University, Melbourne, Australia E-mail: email@example.com
cDepartment of Clinical Hematology, The Alfred Hospital, Melbourne, Australia
dHeart Research Institute, Newtown, Sydney, Australia
eHaematology Department, Monash Health, Clayton, Australia